1. Search Result
Search Result
Results for "

Doxorubicin-

" in MedChemExpress (MCE) Product Catalog:

211

Inhibitors & Agonists

1

Screening Libraries

6

Fluorescent Dyes

13

Biochemical Assay Reagents

21

Peptides

45

Natural
Products

12

Isotope-Labeled Compounds

4

Antibodies

2

Click Chemistry

7

Oligonucleotides

2

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15142
    Doxorubicin hydrochloride
    Maximum Cited Publications
    650 Publications Verification

    Hydroxydaunorubicin hydrochloride; ADR

    Topoisomerase ADC Payload AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial Fluorescent Dye Infection Cancer
    Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride; ADR), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy .
    Doxorubicin hydrochloride
  • HY-100489
    TBHQ
    120+ Cited Publications

    tert-Butylhydroquinone

    Environmental Pollutants Keap1-Nrf2 ERK Autophagy Apoptosis Ferroptosis Cancer
    TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2 . TBHQ (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma .
    TBHQ
  • HY-13624A
    Epirubicin hydrochloride
    35+ Cited Publications

    4'-EpiDoxorubicin hydrochloride

    DNA/RNA Synthesis Topoisomerase Apoptosis Antibiotic Infection Neurological Disease Inflammation/Immunology Cancer
    Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .
    Epirubicin hydrochloride
  • HY-16700

    ADC Payload Topoisomerase Cancer
    PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.
    PNU-159682
  • HY-15142R
    Doxorubicin hydrochloride (Standard)
    5 Publications Verification

    Hydroxydaunorubicin hydrochloride (Standard); ADR (Standard)

    Reference Standards Topoisomerase ADC Payload AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial Fluorescent Dye Infection Cancer
    Doxorubicin hydrochloride (Standard) is the analytical standard of Doxorubicin hydrochloride. This product is intended for research and analytical applications. Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy .
    Doxorubicin hydrochloride (Standard)
  • HY-13624
    Epirubicin
    35+ Cited Publications

    4'-EpiDoxorubicin

    DNA/RNA Synthesis Topoisomerase Apoptosis Antibiotic Cancer
    Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin inhibits DNA and RNA synthesis. Epirubicin is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .
    Epirubicin
  • HY-116063
    Doxorubicin-SMCC
    1 Publications Verification

    Drug-Linker Conjugates for ADC Cancer
    Doxorubicin-SMCC is a agent-linker conjugate for ADC. Doxorubicin-SMCC contains a non-cleavable ADC linker and a DNA topoisomerase II inhibitor Doxorubicin .
    Doxorubicin-SMCC
  • HY-15142A

    Hydroxydaunorubicin

    ADC Payload Antibiotic Bacterial Topoisomerase AMPK HIV Autophagy Mitophagy Apoptosis HBV Fluorescent Dye Infection Cancer
    Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy .
    Doxorubicin
  • HY-16261
    Aldoxorubicin
    20+ Cited Publications

    INNO-206; DOXO-EMCH

    Topoisomerase ADC Payload Cancer
    Aldoxorubicin (INNO-206) is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.
    Aldoxorubicin
  • HY-15794
    Nemorubicin
    1 Publications Verification

    Methoxymorpholinyl Doxorubicin; FCE 23762; PNU 152243

    G-quadruplex Cancer
    Nemorubicin (Methoxymorpholinyl doxorubicin) is a Doxorubicin derivative with potent antitumor activity. Nemorubicin is highly cytotoxic to a variety of tumor cell lines presenting a multidrug-resistant phenotype. Nemorubicin not only intercalate into the duplex DNA, but also result in significant ligands for G-quadruplex DNA segments, stabilizing their structure. Nemorubicin requirs an intact nucleotide excision repair (NER) system to exert its activity .
    Nemorubicin
  • HY-P3669

    ADC Linker Drug Intermediate Cancer
    Gly-Gly-Phe-Gly is a peptide spacer and can be applied to Doxorubicin (HY-15142A) (DXR) conjugates. Gly-Gly-Phe-Gly can be used as an ADC linker to synthesize ADCs, such as Puxitatug samrotecan (AZD 8205) (HY-171689) .
    Gly-Gly-Phe-Gly
  • HY-W190927

    MC-Val-Cit-PAB-Doxorubicin

    Drug-Linker Conjugates for ADC Cancer
    MC-Val-Cit-Doxorubicin (MC-Val-Cit-PAB-Doxorubicin) is drug-linker conjugate for ADC. The maleimide can conjugate with thiol containing molecules. Doxorubicin is an anthracycline antibiotic with antineoplastic activity
    MC-Val-Cit-Doxorubicin
  • HY-B0006B

    (S)-BM 14190

    Adrenergic Receptor Cardiovascular Disease
    (S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX) .
    (S)-Carvedilol
  • HY-16261B
    MC-DOXHZN hydrochloride
    5 Publications Verification

    (E/Z)-AlDoxorubicin hydrochloride; Doxorubicin(6-maleimidocaproyl)hydrazone hydrochloride

    ADC Payload Topoisomerase Cancer
    MC-DOXHZN ((E/Z)-Aldoxorubicin; Doxorubicin(6-maleimidocaproyl)hydrazone) hydrochloride is an albumin-binding proagent of Doxorubicin (HY-15142A) (DNA topoisomerase II inhibitor), with acid-sensitive properties. MC-DOXHZN hydrochloride can be used to synthesize ADC .
    MC-DOXHZN hydrochloride
  • HY-N2591

    Endogenous Metabolite Cancer
    Isocorydine is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .
    Isocorydine
  • HY-N6635

    Fungal Infection Cancer
    trans-Nerolidol improves the anti-proliferative effect of Doxorubicin (DOX) (HY-15142A) against intestinal cancer and breast cancer cells in vitro. trans-Nerolidol increases accumulation of DOX inside cells in vitro. trans-Nerolidol activates apoptosis in vivo .
    trans-Nerolidol
  • HY-G0022

    13-Dihydroadriamycin hydrochloride

    Drug Metabolite Cancer
    Doxorubicinol hydrochloride (13-Dihydroadriamycin hydrochloride) is a secondary alcohol metabolite of Doxorubicin .
    Doxorubicinol hydrochloride
  • HY-W067427
    BAY32-5915
    1 Publications Verification

    IKK Cancer
    BAY32-5915 is a potent IKKα inhibitor with an IC50 value of 60 nM. BAY32-5915 has not affect Doxorubicin (HY-15142A)-induced NF-κB activation .
    BAY32-5915
  • HY-117071

    Ro 115-1240

    Adrenergic Receptor Apoptosis Cardiovascular Disease Endocrinology
    Dabuzalgron (Ro 115-1240) is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function .
    Dabuzalgron
  • HY-121309
    Doxorubicinone
    2 Publications Verification

    Adriamycin aglycone; Adriamycinone

    NF-κB TNF Receptor Interleukin Related Drug Derivative Inflammation/Immunology Cancer
    Doxorubicinone (Adriamycin aglycone) is the aglycone of the antibiotic Doxorubicin (HY-15142A), i.e., its sugar-free parent nucleus structure. Doxorubicinone does not induce DNA damage or bind to RelA, but still downregulates the expression of pro-inflammatory cytokines (such as TNF, IL-12, etc.) regulated by the NF-κB pathway. Doxorubicinone can be used in sepsis-related research .
    Doxorubicinone
  • HY-16532

    AEZS-108; AN-152

    Peptide-Drug Conjugates (PDCs) GnRH Receptor Cancer
    Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro .
    Zoptarelin doxorubicin
  • HY-176806

    Doxorubicin-LNAA-Boc

    Drug Derivative Cancer
    Legubicin (Doxorubicin-LNAA-Boc) is a novel conjugate of Doxorubicin (HY-15142A) and a Legumain-cleavable peptide linker. Legubicin is activated by Legumain to release leucine-doxorubicin while sparing normal tissues. Legubicin inhibits tumor cell growth and reduces DNA binding in non-legumain expressing cells. Legubicin completely arrests tumor growth in mice bearing CT26 tumors. Legubicin can be used for the study of colon carcinoma (CRC) .
    Legubicin
  • HY-136288

    Drug-Linker Conjugates for ADC Cancer
    Azide-PEG4-VC-PAB-Doxorubicin is a agent-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody agent conjugate (ADC) . Azide-PEG4-VC-PAB-Doxorubicin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    Azide-PEG4-VC-PAB-Doxorubicin
  • HY-D0226

    1,4-Dihydroxyanthraquinone

    DNA/RNA Synthesis Fungal Infection Cancer
    Quinizarin (1,4-Dihydroxyanthraquinone), a part of the anticancer agents such as Doxorubicin, Daunorubicin, and Adriamycin, interacts with DNA by intercalating mode (Kd=86.1 μM). Quinizarin is used as a fungicide and pesticide chemical and has shown the ability to inhibit tumor cell growth .
    Quinizarin
  • HY-120504
    N-Acetyltyramine
    1 Publications Verification

    Bacterial Infection Cancer
    N-Acetyltyramine is a quorum-sensing inhibitor (QSI) compound produced by V. alginolyticus M3-10. N-Acetyltyramine is capable of inhibiting the QS of C. violaceum ATCC 12472. N-acetyltyramine reverses resistance in Doxorubicin-resistant leukemia P388 cells .
    N-Acetyltyramine
  • HY-153797

    Biotin Labeled Doxorubicin

    ADC Payload Antibiotic Bacterial Topoisomerase AMPK HIV HBV Apoptosis Autophagy Mitophagy Infection Cancer
    Dox-btn2 is a biotin labeled Doxorubicin (HY-15142A), with a biotin label at the point of conjugation to doxorubicin at 3'-NH2. Dox-btn2 can be used for cell imaging. While Doxorubicin is mainly accumulated in the nucleus, while Dox-btn2 is mainly located in the cytoplasm .
    Dox-btn2
  • HY-16261A

    (E/Z)-AlDoxorubicin; Doxorubicin(6-maleimidocaproyl)hydrazone

    ADC Payload Topoisomerase Cancer
    MC-DOXHZN ((E/Z)-Aldoxorubicin; Doxorubicin(6-maleimidocaproyl)hydrazone) is an albumin-binding proagent of Doxorubicin (HY-15142A) (DNA topoisomerase II inhibitor), with acid-sensitive properties. MC-DOXHZN can be used to synthesize ADC .
    MC-DOXHZN
  • HY-B1041A

    Pimagedine; GER-11free base ; Aminoguanidinium

    NO Synthase Apoptosis Endocrinology
    Aminoguanidine (Pimagedine hydrochloride) is an inhibitor of diamine oxidase and nitric oxide synthase. Aminoguanidine has a dose-dependent inhibitory effect on apoptosis induced by Doxorubicin (HY-15142). Aminoguanidine has antioxidant properties. Aminoguanidine can be used in diabetic nephropathy research .
    Aminoguanidine
  • HY-W441002

    Drug Derivative Drug Intermediate Cancer
    DSPE-succinic acid is a derivative of Succinic acid (HY-N0420) and an intermediate of DSPE-Doxorubicin. DSPE-succinic acid can be used to synthesize DSPE-Doxorubicin via EDC/NHS activation. DSPE-succinic acid is applicable to the research of triple-negative breast cancer .
    DSPE-succinic acid
  • HY-N1514

    P-glycoprotein Cancer
    Ganoderenic acid B is a lanostane-type triterpene isolated from Ganoderma lucidum. Ganoderenic acid B exhibits potent reversal effect on ABCB1-mediated multidrug resistance of HepG2/ADM cells to Doxorubicin .
    Ganoderenic acid B
  • HY-119823

    P-glycoprotein Cancer
    PGP-4008 is a specific P-glycoprotein (Pgp) inhibitor. PGP-4008 inhibits tumor growth in a murine syngeneic Pgp-mediated multiple agent resistance (MDR) solid tumor model when given in combination with Doxorubicin .
    PGP-4008
  • HY-160774

    Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Val-Cit-PABC-DOX (compound 10109), an epsilon-poly-L-lysine-based drug conjugate, is an agent-linker conjugate for ADC by using a DNA topoisomerase I and topoisomerase II inhibitor, Doxorubicin (HY-15142), linked via the linker, Val-Cit-PABC .
    Val-Cit-PABC-DOX
  • HY-158329

    N-Alloc Doxorubicin

    Apoptosis Topoisomerase Antibiotic AMPK Bacterial Autophagy Mitophagy HIV HBV Cancer
    Alloc-DOX (N-Alloc doxorubicin) is a Doxorubicin (HY-15142A) prodrug. The combination of a catalyst (such as nano-palladium) and alloc-DOX leads to a decrease in cell viability and tumour growth .
    Alloc-DOX
  • HY-15142AS1

    Hydroxydaunorubicin-13C,d3 TFA

    Isotope-Labeled Compounds Antibiotic Endogenous Metabolite Infection Cancer
    Doxorubicin- 13C,d3 TFA is the deuterium and 13C labeled Doxorubicin. Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stoppin
    Doxorubicin-13C,d3 TFA
  • HY-177083

    AVA-6000

    FAP Cancer
    Faridoxorubicin (AVA-6000) is a prodrug targeting fibroblast activation protein α (FAPα). Faridoxorubicin releases active doxorubicin through FAPα-mediated cleavage, enhancing intratumoral drug exposure and reducing cardiac toxicity. Faridoxorubicin is promising for research of solid tumors (e.g., colorectal cancer liver metastasis) .
    Faridoxorubicin
  • HY-152965

    Topoisomerase Antibiotic Apoptosis Autophagy Infection Cancer
    Biotin-doxorubicin is a Biotin-labeled Doxorubicin. Doxorubicin, a broad-spectrum anthracycline antibiotic, is a topoisomerase II inhibitor .
    Biotin-doxorubicin
  • HY-141158

    ADC Linker Cancer
    N-(Iodoacetamido)-Doxorubicin is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
    N-(Iodoacetamido)-Doxorubicin
  • HY-162324

    Survivin Cancer
    MX106-4C is a survivin inhibitor that selectively kills ABCB1-positive colorectal cancer cells. MX106-4C can exert synergistic anticancer effects with Doxorubicin or resensitize drug-resistant ABCB1 cells to Doxorubicin .
    MX106-4C
  • HY-P10759

    Peptide-Drug Conjugates (PDCs) Aminopeptidase Cancer
    DTS-201 sodium (CPI-0004Na) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer .
    DTS-201 sodium
  • HY-P11153

    Estrogen Receptor/ERR Cancer
    HGH fragment 176-191 is a fragment of Human Growth Hormone. HGH fragment 176-191 binds with high affinity to Ki-67, MiB protein, and the estrogen receptor. HGH fragment 176-191 enhances the toxicity of Doxorubicin (HY-15142A)-loaded Chitosan nanoparticles against breast cancer .
    HGH fragment 176-191
  • HY-13745

    MEN 10755

    Topoisomerase Cancer
    Sabarubicin is a doxorubicin disaccharide analogue with striking antitumor activity. Sabarubicin is more effective than doxorubicin as a topoisomerase II poison and stimulated DNA fragmentation at lower intracellular concentrations.
    Sabarubicin
  • HY-129410

    Endogenous Metabolite Others
    ADR-925 is an active chelated iron metabolite with the ability to protect neonatal rat cardiomyocytes from doxorubicin (HY-15142A)-induced damage .
    ADR-925
  • HY-125807

    G Protein-coupled Receptor Kinase (GRK) Apoptosis Reactive Oxygen Species (ROS) Akt p38 MAPK Cardiovascular Disease Cancer
    IS20 is a Prokineticin receptor 1 (PKR1) agonist. IS20 diminishes Doxorubicin (HY-15142A) mediated apoptosis and ROS production by activating Akt or MAPK pathways. IS20 protects the heart against Doxorubicin-induced cardiovascular toxicity and improves the survival rate and cardiac function in mouse models. IS20 does not alter the cytotoxicity and antitumor activity of acute DOX treatment in breast cancer cells and MDA-MB-231 xenograft mouse models. IS20 can be used for cancers research .
    IS20
  • HY-154797

    Topoisomerase Cancer
    N,N-Dimethyldoxorubicin is a Doxorubicin (HY-15142A) analogue. N,N-Dimethyldoxorubicin shows cytotoxicity against a panel of tumor cell lines (IC50s < 0.3 μM) .
    N,N-Dimethyldoxorubicin
  • HY-N3486

    Autophagy Cardiovascular Disease
    Isodunnianol is a autophagy inducer. Isodunnianol induces autophagy and increases he expression of pAMPK172, pULK1555,decreases teh expression of pULK1757, SQSTM2. Isodunnianol decreases Doxorubicin (HY-15142A)-induced cardiotoxicity .
    Isodunnianol
  • HY-146391

    P-glycoprotein Cancer
    P-gp inhibitor 4 (Compound 8b) is a selective P-glycoprotein modulator with an EC50 of 94 nM. P-gp inhibitor 4 increases agent transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells .
    P-gp inhibitor 4
  • HY-W440899

    Liposome Others
    DSPE-PEG1000-SPDP is a thiol reactive PEG lipid. The polymer is amphiphilic and spontaneously forms lipid bilayer in water. It can be used to encapsulate nutrients or therapeutics for targeted drug delivery, for example mRNA or DNA vaccine, liposomal doxorubicin for anti tumor.
    DSPE-PEG1000-SPDP
  • HY-16261C

    INNO-206 hydrochloride; DOXO-EMCH hydrochloride

    Topoisomerase ADC Payload Cancer
    Aldoxorubicin (INNO-206) hydrochloride is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin hydrochloride (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.
    Aldoxorubicin hydrochloride
  • HY-130908

    Biochemical Assay Reagents Cancer
    11-Maleimidoundecanoic acid is a maleimide-containing hydrophobic core former. 11-Maleimidoundecanoic acid forms a hydrophobic core via maleimide-thiol coupling with cysteine residues on polypeptides, enabling stable loading and controllable release of Doxorubicin (HY-15142A). 11-Maleimidoundecanoic acid can be used for the research of breast cancer .
    11-Maleimidoundecanoic acid
  • HY-145427

    DNA-PK Cancer
    NU5455 is a potent, selective, and orally active inhibitor of DNA-PKcs. NU5455 administration increases both the efficacy and the toxicity of a parenterally administered topoisomerase inhibitor. NU5455 enhances the activity of Doxorubicin released locally in liver tumor xenografts without inducing any adverse effect .
    NU5455

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: